Focused On-demand Library for Mitochondrial import inner membrane translocase subunit Tim8 A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O60220

UPID:

TIM8A_HUMAN

Alternative names:

Deafness dystonia protein 1; X-linked deafness dystonia protein

Alternative UPACC:

O60220; B2R5A6; Q6IRW6

Background:

Mitochondrial import inner membrane translocase subunit Tim8 A, also known as Deafness dystonia protein 1 and X-linked deafness dystonia protein, plays a crucial role in mitochondrial function. It acts as a chaperone, facilitating the import and insertion of multi-pass transmembrane proteins into the mitochondrial inner membrane and aiding in the transfer of beta-barrel precursors. This protein is essential for the proper functioning of the mitochondrial membrane system, impacting cellular energy production and metabolism.

Therapeutic significance:

Mitochondrial import inner membrane translocase subunit Tim8 A is linked to Mohr-Tranebjaerg syndrome, a disorder characterized by sensorineural deafness, dystonia, and neurologic decline. Understanding the role of this protein could open doors to potential therapeutic strategies for treating or managing this debilitating condition.